How should a named comparison be read?
A named comparison can indicate which providers merit a first enquiry, what each is structurally suited to, and where the known difficulties sit. It cannot promise an account, since within this category acceptance operates per merchant, and the same provider approves one pharmacy whilst declining another on product mix, volumes, history and the quality of the file. Every entry below therefore carries a stance line, recording what the provider's published terms and credible reporting indicate at 27 July 2026, and every verdict concludes at the same point, namely the one-line filter, in writing, for the reader's own pharmacy. Where this article and a provider's written answer diverge, the written answer governs.
The assessment framework comprises the ten criteria from the buyer's guide, compressed to the four which separate providers most in practice, being pharmacy stance, recurring-billing quality, platform fit, and the terms governing reserves and exit. The disclosure from the standfirst warrants repetition within the body, in that this site's publisher builds pharmacy checkouts and holds partner or integration relationships with certain providers named, including Mollie. No provider paid to appear, and the market-wide guidance, comprising filter first and contract against the criteria, remains provider-agnostic.
What does the field look like?
| Provider or tier | Type | Pharmacy stance (as published or reported, Jul 2026) | Best suited to |
|---|---|---|---|
| Mollie | European PSP, UK-active | Onboards pharmacies with enhanced documentation, with category approved per merchant at registration | Independent online pharmacies, and Shopify or custom builds seeking a modern stack |
| PayPal | Wallet and PSP | Pharmaceuticals within pre-approval categories under its Acceptable Use Policy | A conversion-lifting wallet alongside a card backbone, following pre-approval |
| Stripe | Global PSP | Restricted-category terms, requiring explicit support, with self-serve unsuitable | Only with written category acceptance, failing which it becomes the case study |
| Worldpay, Barclaycard and peers | Traditional UK acquirers | Board pharmacies through full underwriting, with long in-store pharmacy heritage | Established pharmacies seeking bank-grade acquiring across in-store and online |
| High-risk specialists (Total Processing, Trust Payments, emerchantpay among others) | Specialist acquirers and PSPs | Market openly to regulated sectors including pharmacy, with acceptance per file | Higher-risk mixes, subscription-heavy models, and merchants declined upstream |
| Enterprise platforms (Checkout.com among others) | Enterprise PSP and acquirer | Regulated verticals considered case by case at commercial scale | Scaled operators holding volume sufficient to negotiate |
What of Mollie?
Mollie is an Amsterdam-founded PSP operating across the UK and more than thirty European countries, holding PCI DSS Level 1, supporting more than thirty-five payment methods spanning cards, wallets and local European options, pricing on a transaction basis without monthly fees or long-term contracts, settling daily, and providing native tooling for the recurring payments upon which treatment plans depend.
Its relevance to this list derives from a stance shift. As of late 2025 into 2026, Mollie is reported and observed to onboard UK pharmacies, with enhanced supporting documentation required during compliance checks, encompassing registration, superintendent details and website review, being the underwriting file which the high-risk analysis recommends preparing. Its user terms render the mechanics explicit, in that activities are approved at registration, a prohibited list applies, and Mollie retains discretion to decline risk it does not wish to hold, which is to say that acceptance is genuine and per merchant, precisely as the filter assumes.
The strengths in pharmacy use comprise clean integrations for Shopify, WooCommerce and custom builds, which matters doubly given the Shopify native-payments constraint, genuinely broad European payment-method coverage where a merchant serves beyond cards, and an onboarding which, with the file prepared, runs in days rather than the weeks which acquirer underwriting requires.
Two matters warrant attention. It constitutes a PSP relationship rather than the merchant's own acquiring account, such that portfolio risk policy applies and the freeze-protocol and token-portability questions from the criteria guide should be asked before dependence rather than afterwards. And approval covers the mix declared, such that a later expansion into higher-risk lines returns through compliance, declared rather than discovered. The verdict, in mid-2026, is that Mollie constitutes the strongest first shortlist entry for a typical independent UK online pharmacy, subject to the disclosure above, which invites the reader to apply the filter to this assessment as well.
What of PayPal?
PayPal at a pharmacy checkout constitutes two different products presenting as one button. As a wallet, it measurably improves conversion among a segment of customers who trust it more readily than entering card details, and that segment skews toward precisely the cautious first-time patient which a new pharmacy wishes to convert. As primary rails, it is the wrong instrument, since its Acceptable Use Policy places pharmaceutical sales among the activities requiring pre-approval, and operating without that approval amounts to volunteering for the account-limitation process with the merchant's float inside it.
The appropriate sequence therefore runs card backbone first with a provider from this list, then PayPal's pre-approval route applied for with GPhC registration, certification and a compliant site evidenced, then the button added as a conversion feature rather than a foundation. Approved and positioned in that manner it earns its place, whilst treated as the entire payment stack it concentrates every risk described throughout this cluster within a single non-acquiring relationship. One operational note warrants adding, in that PayPal disputes run through its own resolution machinery alongside card chargebacks, such that the dispute-design habits from the criteria guide, comprising recognisable descriptors, dispatch evidence and straightforward cancellation, apply with an additional venue attached.
What of Stripe, handled honestly?
Stripe belongs within this article because every founder enquires about it, and it warrants an honest paragraph rather than dismissal. It is excellent payments technology, offering the developer experience which the remainder of the market imitates, and its restricted-business terms have historically treated pharmaceuticals as a category requiring explicit support, which its instant self-serve onboarding does not provide.
That mismatch, rather than any hostility, explains why Stripe features prominently within the sector's account-loss accounts. Undeclared pharmacies board within minutes, trade for months, and encounter the risk team at volume, which is the sequence the companion analysis identifies as the characteristic failure. The honest position is that a merchant wishing to use Stripe should ask Stripe, in writing, before building, whether its registered pharmacy at its mix is supportable. Certain regulated-healthcare merchants do operate on the platform under explicit arrangements, and where such an arrangement is secured the technology is excellent. Where the answer is negative or absent, that constitutes the answer, and routing around it through a softened business description is the single course which this cluster prohibits. The verdict is accordingly that a written acceptance renders it viable whilst anything less renders it the case study.
What of the traditional acquirer route?
The UK's established acquirers, of which Worldpay and Barclaycard Payments are the familiar names among several, have banked bricks-and-mortar pharmacy for decades, and the terminal upon most dispensary counters answers to one of them. For card-not-present pharmacy they remain fully available through the front door, comprising full underwriting, the scheme registrations which the category requires, and timelines measured in weeks.
What that purchases is substance rather than speed, namely the merchant's own account with an FCA-supervised institution of scale, contracted terms, and a counterparty whose risk decision was individual rather than algorithmic. What it costs is onboarding friction, generally less modern developer tooling than the PSP tier provides, and pricing which rewards negotiation and volume rather than defaulting to reasonable. The verdict is that this constitutes the natural home for established pharmacies unifying in-store and online acquiring, for operators valuing bank-grade stability above stack elegance, and for any merchant whose volumes justify negotiating interchange-plus properly. It is over-engineered as a first rail for a small launch, which is the function the PSP tier serves.
What of the high-risk specialists?
Between the mainstream and the offshore market sits a legitimate tier which the criteria guide anticipated, comprising onshore, FCA-supervised acquirers and PSPs which market openly to regulated and higher-risk sectors, with pharmacy named among them. Names which UK operators will encounter include Total Processing, Trust Payments and emerchantpay, among others.
Their economics are candid about the category, comprising pricing above mainstream retail, reserves in most cases, and genuine underwriting, in exchange for a counterparty whose business consists precisely of merchants of this kind, with dispute tooling, MIT-competent gateways and account management accustomed to regulated files. Their pharmacy marketing should be treated as an invitation rather than a promise, since acceptance still turns upon the file, and the filter, the ten written questions and the contract-clause review apply at full strength, with reserves and exit terms warranting particular attention given that specialist contracts vary more widely than mainstream ones.
The verdict is that this tier suits product mixes which the PSPs decline, including controlled-drug-adjacent lines and aggressive subscription models, together with merchants rebuilding following a termination, and constitutes a sensible second relationship for continuity once a primary rail is stable. The line to observe is jurisdictional. Onshore and supervised constitutes a tier, whilst offshore and guaranteed constitutes the trap, and no shortage of brokers will attempt to walk a merchant from one to the other.
What of the enterprise platforms?
At scale the conversation changes vendors. Enterprise platforms, of which Checkout.com is the name most frequently encountered from London, combine PSP-grade technology with acquiring and treat regulated verticals as commercial negotiations rather than as categories to be checked. For a pharmacy group or a scaled digital-health operator the proposition is genuine, comprising negotiated interchange-plus pricing, dedicated risk and account teams, multi-entity and multi-currency structures, and engineering support for a stack which by that stage includes subscriptions, wallets and possibly in-store acceptance.
The gate is volume, in that these relationships are secured with forecasts in the millions, and the diligence comprises the same criteria examined more closely, with exit and token portability mattering more rather than less once a migration would involve seven figures of stored mandates. The verdict is that this is not a first rail but the destination negotiation for operators whose growth has earned it, ideally conducted with genuine statements from two existing providers available.
What has been excluded, and why?
Three absences are deliberate. Buy now, pay later is excluded because consumer credit at a medicines checkout raises affordability and ethical questions which this site argues separately, and because the major providers' own category rules are restrictive around healthcare. The exclusion rests on principle rather than oversight. The offshore high-risk brokers are excluded for the reasons this cluster has already set out, in that an ecosystem whose defining characteristic is serving the declined has no place upon a registered pharmacy's shortlist. Crypto-settlement gateways are excluded on the same reasoning. Where a proposition from any of the three arrives presented as innovation, the criteria guide's section on disqualifying responses has already composed the reply.
What does the file which secures approval contain?
Every provider on this list, from Mollie's enhanced-documentation onboarding through to a specialist's full underwriting, is reading versions of a single file, which should accordingly be constructed once and submitted everywhere.
The core pack comprises incorporation documents with directors and beneficial owners identifiable, the GPhC premises registration and superintendent details presented prominently, since these are the artefacts which reclassify a merchant from anonymous category risk into a named regulated business, the product list with legal classifications stated across GSL, P and POM with any controlled-drug lines flagged rather than obscured, since an underwriter discovering them subsequently has discovered a misrepresentation, the prescribing model expressed in one paragraph which a banker can follow, covering who prescribes, how patients are assessed and where the remote prescribing standards are satisfied, certification status whether held or in progress, realistic volume and average-order forecasts which the merchant intends to remain within, bank details and the identity checks which payment law requires, and the website itself, sufficiently complete to be read as the underwriting artefact it is, with terms, privacy notice, refund policy and the prescription flow all visible.
Provider-specific additions then attach. Mollie's compliance checks require the enhanced documentation supplied during application. PayPal's route runs through its pre-approval process with the AUP category named. The specialists and acquirers add financials and, for young companies, the personal-guarantee discussion which the criteria guide recommends negotiating rather than accepting.
Two habits preserve an approval once obtained. Providers' policy pages warrant monitoring in the manner applied to GPhC updates, since the stances recorded here are dated for a reason. And every product-mix expansion should be routed through a declared approval before launch, since the account which fails is almost never the one which was refused but the one which quietly outgrew what it was approved for.
What are the verdicts by scenario?
Launching an independent online pharmacy on Shopify or a custom build. Shortlist Mollie together with one specialist, apply the filter and the written questions to both, and add PayPal by pre-approval once the card rail is operational.
Established community pharmacy adding online sales. Commence with the existing acquirer, which already banks the business, and benchmark its card-not-present quote against a PSP before signing, since incumbency constitutes a convenience rather than a price.
Subscription-heavy treatment-plan model. Weight the decision toward MIT mechanics, dispute tooling and token portability, which favours the specialist tier and the enterprise platforms as scale increases, and examine whichever provider is chosen against the recurring-billing questions verbatim.
Higher-risk product mix or post-termination rebuild. The onshore specialists, with contract-clause review treated as non-negotiable.
Scaled group. Take two genuine months of statements to the enterprise tier and negotiate.
Every scenario concludes identically. Whatever this article has caused a reader to shortlist, the provider's written acceptance of that pharmacy, that mix and those volumes is the only sentence which binds anyone, and the launch timeline should schedule obtaining it among the first tasks rather than the last.
Key takeaways
- Named lists map the field without granting accounts. Acceptance operates per merchant, stances are dated 27 July 2026, and written confirmation for a specific mix outranks every sentence here.
- Mollie constitutes the strongest typical first shortlist entry in mid-2026, offering pharmacy onboarding with enhanced documentation, modern integrations, recurring tooling and per-merchant approval, subject to the noted disclosure that this site's publisher is a partner.
- PayPal functions as a conversion-lifting wallet following pre-approval under its Acceptable Use Policy, and as an account limitation waiting to occur without it. Backbone first, button second.
- Stripe is viable only with explicit written category acceptance, since its self-serve onboarding and pharmacy's underwriting requirements constitute a structural mismatch, and softened descriptions are prohibited by this cluster's first rule.
- Traditional acquirers offer bank-grade substance through full underwriting, onshore specialists legitimately serve harder mixes at candid prices, and enterprise platforms constitute the destination negotiation which volume earns.
- BNPL, offshore brokers and crypto gateways are excluded deliberately, on ethical, risk and principled grounds respectively.
- Whatever the shortlist, apply the filter first, put ten questions in writing, compute effective rates, review the contract clauses, and schedule the payments file at the commencement of the launch plan.
FAQs
Checkouts we build every week.
Our publisher integrates pharmacy checkouts across the providers in this article, Mollie included, with the documentation packs that get pharmacy applications approved, recurring billing wired correctly, and orders flowing into Dataforge PMR. If you want the shortlist turned into a live, compliant checkout, see how it works.
See Dataforge PMR